Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M106300200 on August 14, 2001

J. Biol. Chem., Vol. 276, Issue 42, 39226-39231, October 19, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/42/39226    most recent
M106300200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Theiler, R. N.
Right arrow Articles by Compton, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Theiler, R. N.
Right arrow Articles by Compton, T.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Characterization of the Signal Peptide Processing and Membrane Association of Human Cytomegalovirus Glycoprotein O*

Regan N. TheilerDagger and Teresa Compton§

From the McArdle Laboratory for Cancer Research, University of Wisconsin-Madison Medical School, Madison, Wisconsin 53706

Received for publication, July 5, 2001, and in revised form, August 9, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Human cytomegalovirus (HCMV) has a structurally complex envelope that contains multiple glycoproteins. These glycoproteins are involved in virus entry, virus maturation, and cell-cell spread of infection. Glycoprotein H (gH), glycoprotein L (gL), and glycoprotein O (gO) associate covalently to form a unique disulfide-bonded tripartite complex. Glycoprotein O was recently discovered, and its basic structure, as well as that of the tripartite complex, remains uncharacterized. Based on hydropathy analysis, we hypothesized that gO could adopt a type II transmembrane orientation. The data presented here, however, reveal that the single hydrophobic domain of gO functions as a cleavable signal peptide that is absent from the mature molecule. Although it lacks a membrane anchor, glycoprotein O is associated with the membranes of HCMV-infected cells. The sophisticated organization of the gH·gL·gO complex reflects the intricate nature of the multicomponent entry and fusion machinery encoded by HCMV.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The family Herpesviridae contains eight medically significant human pathogens. These viruses are large, enveloped double-stranded DNA viruses that establish life-long latent infections within their hosts. Human cytomegalovirus (HCMV)1 causes multiple clinical sequelae in immunocompromised hosts. HCMV is able to enter and infect a wide variety of host cell types and can cause disease in most organs of the body (1). This broad tropism can be attributed in part to a complex set of viral envelope glycoproteins that play a vital role in the viral life cycle by mediating entry of the virus into host cells, cell-to-cell spread of infection, and maturation of virions. Most enveloped viruses, including influenza and human immunodeficiency virus, encode a single fusion glycoprotein that initiates attachment and fusion. In contrast, herpesviruses such as herpes simplex virus require a minimum of four glycoproteins for fusion (2). The multicomponent nature of herpesvirus fusion machinery provokes many questions about the mechanisms by which large viruses with multiple glycoproteins achieve membrane fusion.

HCMV enters host cells by a sequential cascade of molecular events involving multiple viral and cellular proteins, culminating with fusion of the envelope with the cellular plasma membrane (3, 4). At least two HCMV envelope complexes are required for fusion, the homodimeric glycoprotein B (gB), and a heteroligomeric complex thought for many years to be composed of glycoprotein H and glycoprotein L (5-7). Glycoprotein B, gH, and gL have homologs throughout the Herpesviridae family (7, 8), and in all cases tested these proteins function at the level of membrane fusion (9-13). Attempts to reconstitute the HCMV gH complex by coexpression of the gH and gL genes, open reading frames UL75 and UL115 of the HCMV genome, respectively (7, 14, 15), were unsuccessful (16, 17). This failure led to the discovery that the HCMV gH complex contained a third distinct gene product encoded by the UL74 open reading frame, a protein now designated gO (18). Interestingly, the UL74 gene has homologs in the genomes of the beta -Herpesvirinae subfamily, which includes HCMV, human herpesvirus 6, and human herpesvirus 7 (18). Thus, while gH/gL heterodimers predominate in other herpesviruses, the HCMV complex is an unusual tripartite complex composed of gH·gL·gO. This complex appears on the surface of HCMV-infected cells and in the envelopes of virions (18, 19). Glycoprotein H is a type I transmembrane protein with a 719-amino acid ectodomain and a short 6-amino acid cytoplasmic tail (15, 20), and expression of gH without gL results in endoplasmic reticulum retention (5, 6). gL lacks a membrane anchor and is disulfide-bonded to gH (5, 7, 15). In contrast to gH and gL, the membrane topology and organization of gO in the tripartite complex are unknown.

Analysis of the amino acid sequence of gO reveals several interesting features, including 18 potential N-glycosylation sites and a single hydrophobic domain that begins 14 amino acids from the N terminus. Hydropathy analysis of this segment shows a 20-22-amino acid region that we predicted to serve as both a signal peptide and a membrane anchor domain (18). This region is unusual for a signal peptide because it is inset from the amino terminus and it is long enough to span the bilayer as a membrane anchor. If uncleaved by signal peptidase, this region (a signal/anchor domain) would anchor gO in a type II membrane orientation with a cytosolic amino terminus and a carboxyl-terminal extracellular domain. In this work, we describe experiments demonstrating that, like glycoprotein L, glycoprotein O is a soluble protein that associates with cellular and viral membranes.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cells and Viruses

Human foreskin fibroblasts and immortalized fibroblasts were cultured as previously described (21). Human cytomegalovirus strain AD169 was propagated and titered as previously described (21). 293-T cells were grown in Dulbecco's modified Eagle medium supplemented with 1% penicillin-streptomycin-fungizone, 0.3% glutamine, and 10% fetal bovine serum (Harlan Biosciences).

Plasmids

All polymerase chain reaction steps were performed using Pfu high fidelity polymerase (Stratagene). Oligonucleotides were synthesized at the University of Wisconsin Biotechnology Center DNA facility, where the final constructs were also verified by automated DNA sequencing. pCaggs.gO was produced by polymerase chain reaction amplification of the full-length gO coding region using primers 5'-GGAATTCACCATGGGGAGAAAAGAGATG-3' and 5'-AAACCGCTCGAGTTACTGCAACCACCA-3'. The product was cut with EcoRI (5') and XhoI (3') and was inserted into the multiple cloning site of the pCaggs vector (donated by Y. Kawaoka, University of Wisconsin). The gO insert from pCaggs.gO was subcloned into pCDNA3 via EcoRI/XhoI. pCaggs.Delta gO was generated by inserting into the pCaggs vector the region encoding amino acids 33-466 of gO. The Delta gO insert was amplified by polymerase chain reaction from pcDNA3.gO template using primers 5'-GGAATTCACCATGAGTAAAGCGCTTTATAATCGTCCTTG-3' and 5'-AAACCGCTCGAGTTACTGCAACCACCA-3'. The EcoRI/XhoI-digested Delta gO was ligated into the pCaggs multiple cloning site. pcDNA3.Delta gO resulted from subcloning Delta gO from pCaggs into pcDNA3 via EcoRI/XhoI. The pCaggs.His-gO construct encodes the complete gO coding sequence preceded by a six-residue polyhistidine tag. It was generated in the same manner as pCaggs.gO, except that the 5' polymerase chain reaction primer was 5'-GGAATTCACCATGCATCACCATCACCATCACATGGGGAGAAAAGAGATG-3'. pcDNA3.His-gO was generated by subcloning His-gO from pCaggs into pcDNA3 via EcoRI/XhoI.

SDS-PAGE and Immunoblotting

SDS-PAGE and immunoblotting were performed essentially as previously described (17, 18). Briefly, nitrocellulose membranes were washed in TBS containing 0.05% SDS, 0.5% Tween 20, and 20 mg/ml powdered skim milk. Horseradish peroxidase-conjugated secondary antibodies were purchased from Pierce, and activity was detected using Renaissance enhanced chemiluminescence reagent (PerkinElmer Life Sciences). UL74 antiserum (recognizing glycoprotein O) was previously described (18). Immunoblots probed with UL74 antiserum were hybridized and washed in the presence of wash buffer (described above) and additional cell lysate (100 mM dish confluent 293-T, cos-7, or IF cells lysed in 1 ml of 1% SDS). Rabbit polyclonal antibody 6824 was previously described (17). Monoclonal antibody 27-78 was kindly provided by W. Britt. Murine monoclonal antibody recognizing Hsp90 was purchased from Transduction Laboratories. Rabbit polyclonal antiserum recognizing calreticulin was purchased from Stressgen. Rabbit polyclonal anti-His serum (His-probe) was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).

Transfections

Plasmid DNA was purified by polyethylene glycol precipitation (22). Cells were transfected by either calcium phosphate precipitation (23) or genePorter lipid transfection reagent (Gene Transfer Systems) according to the manufacturer's instructions. Calcium phosphate transfections were supplemented with 5 mM sodium butyrate.

Subcellular Fractionation

Preparation of Microsomes-- Immortalized human fibroblasts were either mock-infected or infected with HCMV strain AD169 at a multiplicity of infection of 1. Six days postinfection, the cells were scraped into their media and collected by centrifugation. The cell pellet was suspended in hypotonic lysis buffer (20 mM HEPES, 1.5 mM MgCl2, 2.5 mM EDTA, 1× protease inhibitor mixture/PIC, pH 7.4) and Dounce-homogenized (final volume 15 ml). Nuclei were pelleted at 1500 × g for 10 min and discarded. The supernatant was centrifuged for 30 min at 18,000 × g to pellet microsomal membranes. Supernatant was precipitated with 10% trichloroacetic acid and constitutes the cytosolic fraction. Microsomal membranes were prepared from transiently transfected 293-T cells harvested 48 h post-transfection.

Alkaline Carbonate Extractions-- Microsomal membranes were suspended in 100 µl of buffered sucrose (0.3 M sucrose plus 10 mM Tris, pH 7.5) on ice. The suspension was incubated on ice for 60 min in 5 ml of 0.1 M Na2CO3, pH 11.5, and 100 mM dithiothreitol, followed by centrifugation at 50,000 rpm in a Beckman 70.1Ti rotor (150,000 × g). The pellet was subjected to an additional round of alkaline carbonate extraction under the same conditions. Supernatants from the washes were pooled and precipitated with 10% trichloroacetic acid in the presence of 200 mM iodoacetic acid. Fractions were suspended in Tris base plus nonreducing SDS-PAGE sample buffer containing 200 mM iodoacetic acid, heated to 65 °C, and subjected to SDS-PAGE. One-quarter cell equivalent of the cytosolic fraction, compared with membrane fractions, was analyzed to maintain relative equivalence of protein concentrations among wells. For alkaline carbonate extractions of microsomes from transfected 293-T cells, the dithiothreitol and iodoacetic acid were omitted, and samples were subjected to reducing SDS-PAGE.

In Vitro Transcription/Translation and Immunoprecipitation

In vitro transcription and translation was performed using the TnT T7 Quick coupled transcription/translation kit according to the manufacturer's instructions (Promega). Immunoprecipitation was performed by diluting 45 µl of translation product in 1 ml of RIPA (150 mM NaCl, 50 mM Tris pH 8.0, 1% Nonidet P-40, 0.1% SDS, 0.5% deoxycholate, 1 mM EDTA) plus 0.5% bovine serum albumin. Samples were precleared with protein A beads, followed by incubation overnight with anti-His IgG. Complexes were precipitated with protein A beads, washed five times with RIPA plus bovine serum albumin, and eluted by boiling in RIPA plus reducing SDS-PAGE sample buffer.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Glycoprotein O Is a Membrane-associated Protein-- To test the hypothesis that gO is a type II membrane protein, HCMV-infected cells were subjected to fractionation followed by alkaline carbonate extraction. This technique solubilizes peripheral membrane proteins while leaving transmembrane proteins associated with a membrane pellet (24). Immunoblotting of the resulting cytosolic, carbonate-extracted, and integral membrane proteins revealed that gO partitions in both the peripheral and integral membrane fractions (Fig. 1). A majority of gO consistently segregated with transmembrane proteins, while a lesser amount was detected in the peripheral membrane fraction. Controls for each fraction include Hsp90 (cytosol), calreticulin (soluble endoplasmic reticulum protein), and the cytomegalovirus-encoded proteins gH and gB (both type I integral membrane proteins), all of which were recovered in the appropriate fractions. Because gO was found in both membrane fractions in HCMV-infected cells, we hypothesized that the two types of membrane association may result from interactions of gO with other viral proteins.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 1.   Subcellular fractionation of HCMV-infected fibroblasts. Infected cells were harvested 7 days postinfection and separated into cytosolic (C), peripheral membrane (PM), and transmembrane (TM) fractions. The peripheral membrane fraction consists of proteins removed from membranes by alkaline carbonate treatment, including the ER chaperone protein calreticulin. Transmembrane proteins include those remaining in the membrane after alkaline carbonate treatment as demonstrated by the type I integral membrane proteins gH and gB. Protein fractions were subjected to SDS-PAGE followed by immunoblotting with antibodies to glycoprotein O, Hsp90, calreticulin, glycoprotein H, and glycoprotein B as indicated.

To examine gO in a system isolated from other viral gene products, a similar experiment was conducted using transiently transfected 293-T cells expressing gO (Fig. 2). Although it partitioned differentially in HCMV-infected cells, gO was solely detected in the soluble membrane content fraction of transfected cells. This result, shown in Figs. 1 and 2, demonstrated that gO is more strongly associated with membranes of infected cells than those of transfected cells, suggesting that the affinity of membrane association of gO differs with the context of expression.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 2.   Subcellular fractionation of transfected 293-T cells. 293-T cells were harvested 48 h after transfection with plasmids expressing HCMV gO (top three panels) or gH (bottom panel). Cells were fractionated as in Fig. 1, followed by SDS-PAGE and immunoblotting with antibodies as indicated to the right of each panel.

The Signal Peptide of gO Is Cleaved from the Mature Molecule-- Initial experiments suggested that gO was not a transmembrane protein. We further tested this hypothesis using two recombinant forms of gO (Fig. 3). One form, designated Delta gO, lacked the amino-terminal 32 amino acids comprising the putative signal/anchor domain. A second construct, designated His-gO, encoded a six-residue polyhistidine sequence on the extreme amino terminus of the protein. The full-length peptide backbone of gO was predicted to be 466 amino acids long, with a molecular mass of ~51 kDa (18, 20). Loss of the 32-amino acid N-terminal hydrophobic sequence predicted a protein of ~48 kDa for Delta gO. For comparison of the backbone sizes of gO and Delta gO, N-linked glycans were removed by endoglycosidase H treatment of gO-transfected cell lysates and Delta gO-transfected cell lysates. If the signal peptide of gO were uncleaved, we would expect to see a difference in electrophoretic mobility corresponding to the 3-kDa size difference between the peptide backbones of gO and Delta gO (Fig. 3). As shown in Fig. 4, the deglycosylated peptide backbones of gO and Delta gO migrated similarly when subjected to SDS-PAGE, demonstrating that these proteins were the same 48-kDa size (Fig. 4A) and that the signal peptide of gO was cleaved from the mature protein. The identity of the lower 40-kDa band produced by transfection of Delta gO is unknown but may represent a degradation product. Note also that removal of the signal peptide in Delta gO abolished glycosylation, as evidenced by its electrophoretic mobility and insensitivity to glycosidase digestion. To confirm that experiments performed on gO produced by transfection reflected the forms of gO found in HCMV-infected cells, the peptide backbone size of gO was determined in both infected and transfected cells. Cell lysates were treated with peptide N-glycosidase F to remove all N-linked glycans and were then subjected to SDS-PAGE followed by immunoblotting. The results in Fig. 4B show that the backbone peptide of gO had the same electrophoretic mobility in transfected and infected cells and that signal peptide processing was similar in these two systems.


View larger version (9K):
[in this window]
[in a new window]
 
Fig. 3.   Amino acid sequence of the putative signal/anchor domain. The amino terminus of gO contains a hydrophobic region (underlined), which may serve as both a signal peptide and a membrane anchor domain. Removal of the majority of this domain in the mutant designated Delta gO allows for translation initiation at methionine 33. The addition of an amino-terminal polyhistidine tag in His-gO plasmids allows specific detection of this region after translation.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 4.   The peptide backbone size of gO is consistent with signal peptide cleavage. A, 293-T cells were transfected with plasmids expressing gO (lanes 3 and 4) or Delta gO (lanes 5 and 6). Cells were harvested 48 h post-transfection, lysed in RIPA buffer, and subjected to endoglycosidase H (or mock) treatment. Analysis by SDS-PAGE and immunoblotting demonstrates that the glycan-free backbone of processed gO has equivalent mobility to that expressed by Delta gO. Note that Delta gO does not undergo glycosylation. B, HCMV-infected and mock-infected fibroblasts were harvested on day seven of infection, lysed in RIPA buffer, and subjected to peptide N-glycosidase F digestion. The lane marked Transfected indicates that gO-transfected 293-T cells were lysed and treated with peptide N-glycosidase.

To further test that the N-terminal signal sequence undergoes signal peptidase cleavage, a polyhistidine tag was added to the extreme amino terminus of gO (Fig. 3). Detection of His-gO expression by immunoblotting with anti-gO serum verified that the recombinant construct expressed glycosylated gO, indicating that the tag did not alter signal peptide function (Fig. 5A). Immunoblotting with anti-His serum, however, showed that the tag was absent from processed gO (Fig. 5B). Using in vitro translation, we confirmed that the amino-terminal His tag was translated as part of gO and that it was recognized by our antibody (Fig. 6). Thus, our inability to detect the His tag in cells resulted from cleavage of the amino terminus rather than from internal translation initiation. Additionally, in vitro translation of gO and Delta gO clearly showed a difference in mobility, indicating that their identical electrophoretic mobility upon expression in cells (Fig. 4) resulted from cleavage of the signal peptide during ER translocation.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 5.   The amino-terminal polyhistidine tag is absent from mature gO. Transfected 293-T cells were lysed 48 h post-transfection and subjected to SDS-PAGE and immunoblotting. Left, lysates blotted with anti-gO serum show expression of gO after transfection with pCaggs.gO (gO) or pCaggs.His-gO (His-gO). Right, cell lysates probed with anti-His serum demonstrate the presence of a polyhistidine tag on the control protein encoded by pHM6 (beta -gal His), but not on His-gO.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 6.   The amino-terminal polyhistidine tag is translated. Coupled transcription and translation of the indicated plasmids was driven by the T7 promoter of pcDNA3 or pHM6 in the presence of radiolabeled methionine. Samples were analyzed by SDS-PAGE and autoradiography before (left) or after (right) immunoprecipitation with anti-His serum.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The gH·gL·gO complex undergoes multiple steps of assembly during its transit through the secretory pathway of HCMV-infected cells (19). With a mass greater than 240 kDa, the mature complex is a disulfide-linked heteroligomer of unknown stoichiometry (6, 7, 25, 26). Early studies of HCMV gH and gL showed that gH needs gL for proper trafficking through the secretory apparatus (5, 6). When gH is expressed in the presence of gL, complexes of the two proteins reach the cell surface but are not secreted into the medium. Removal of the C-terminal membrane anchor of gH results in secretion of soluble gH·gL complexes, and when gL is expressed alone it can also be found in the medium (5, 6). These data led to the conclusion that gH contains a C-terminal membrane anchor and that gL is held in the viral envelope by its disulfide linkage(s) to gH. Beyond this basic characterization, little is known about the structure of the gH·gL·gO complex.

Based on sequence analysis, we hypothesized that the 20-amino acid hydrophobic domain on the amino terminus of gO serves as a signal peptide and membrane anchor. In general, a signal peptide longer than 15-18 amino acids indicates that signal peptidase is unlikely to cleave the nascent chain, leaving an intact amino-terminal transmembrane domain (27). Several viral envelope proteins, including influenza neuraminidase, are known to have this membrane orientation (28-30). As a novel member of the disulfide-linked gH·gL complex, gO is unusual in that it is a viral envelope protein that does not need a transmembrane domain for membrane association. Covalent and/or noncovalent association with gH may suffice to tether gO to the viral envelope. Although we hypothesized, based on the amino acid sequence, that gO contained a membrane anchor, we addressed the question experimentally.

One established method for separating integral membrane proteins from soluble, membrane-associated proteins involves washing vesicular membranes in alkaline carbonate. Alkaline treatment converts membrane vesicles into sheets, releasing ER and Golgi contents into the supernatant and leaving transmembrane proteins in the membrane pellet (24). From previous work, it is known that processing of gO in the ER occurs prior to its association with gH·gL complexes and that gO can be found as a monomer for several hours after synthesis (19). We propose that the subset of glycosylated gO that is not stably bound to gH·gL complexes may be the same portion that can be extracted from membranes by alkaline carbonate treatment. Results in Fig. 2 show that gO, when expressed alone, can be completely extracted from membranes. Our results suggest that alkaline carbonate extraction solubilizes proteins from membrane vesicles in a context-specific fashion. The implication of such selective extraction is that proteins, such as gO, that stably associate with integral membrane proteins via noncovalent or covalent interactions cannot be reliably analyzed by alkaline extraction alone.

Faced with the experimental challenge of demonstrating the absence, rather than the presence, of a membrane-spanning domain, we created an epitope-tagged recombinant form of gO. The cumulative evidence from the His-tagged protein experiment and previous studies demonstrated that the signal peptide of gO is cleaved and that gO is a soluble protein. Thus, our working model of the gH·gL·gO complex asserts that glycoproteins H, L, and O are held in the viral envelope by the single transmembrane domain of gH (Fig. 7). We also know that assembly of the complex occurs sequentially in the ER and that gO acquires terminal modifications while traversing the Golgi en route to the cell surface (19). It is not known, however, where final envelopment of the virus occurs.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 7.   Model of HCMV cell entry. HCMV adheres to the surface of human fibroblasts by low affinity interactions between gB and cellular heparan sulfate proteoglycans (3). This adhesion quickly transitions to a state of stable binding, or docking, as gB attaches to its nonheparin cellular receptor (47). Docking also results in activation of an intracellular signal transduction cascade, with characteristics similar to that induced by interferon binding (48, 49). At least one additional step, priming, is necessary for membrane fusion to occur. Binding of the gH·gL·gO complex to unidentified cellular component(s) precedes the final fusion of the viral envelope with cellular membranes (40). Although specific events, such as Ca2+ flux or endosomal acidification, are known to trigger the transition to membrane fusion in other systems, no such trigger has been identified for herpesvirus-mediated membrane fusion.

The tripartite gH·gL·gO complex is unusual among viral fusion glycoproteins and has to date been studied only in HCMV. The gH and gL components of the complex have characterized homologs among all herpesviruses examined (31-37), but gO homologs are found only in the beta  herpesviruses (18). Glycoproteins H and L are essential components of the virus (38) and are necessary for fusion of the viral envelope with the host cell membrane (9, 39, 40). In contrast, recent work has shown that gO is not essential for viral replication in tissue culture but that a gO knockout virus has a severely attenuated phenotype (38). Preliminary data from our laboratory also support involvement of gO in the fusion process, and studies are ongoing to elucidate the exact role that gO plays in viral entry and cell to cell spread of infection.

The Herpesviridae are unique among viruses in the complexity of their glycoprotein coats. Thus, models of membrane fusion derived from single glycoprotein viral systems are of only moderate utility in our efforts to dissect the mechanisms of viral entry and cell to cell spread of HCMV. Perhaps more relevant are models of intracellular vesicle transport and membrane fusion, such as neurotransmitter release from synaptic vesicles. The multiprotein interactions between v-SNAREs and t-SNAREs as well as the sequential nature of membrane docking and fusion steps closely resemble the stages of HCMV fusion with host cell membranes (41). Additionally, the core fusion complex of SNAP-25/syntaxin is composed of an integral membrane protein, syntaxin, which targets SNAP-25 to membranes (42). Several other proteins have been identified that bind to and positively or negatively regulate SNAREs in the neuron, including those proteins mediating calcium-triggered activation of fusion (41, 43, 44). Multiple additional proteins of uncharacterized function have also been identified in the envelope of HCMV (see Refs. 20 and 45; reviewed in Ref. 46) and may contribute to or regulate the fusion machinery in response to unknown triggering events. Examination of the mechanisms of intracellular membrane fusion may ultimately facilitate our understanding of the complex nature of HCMV-induced membrane fusion.

    FOOTNOTES

* This research was funded by United States Public Health Service Grant RO1 A144203.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Supported by Molecular Biosciences Training Grant T32 GM 07215.

§ To whom correspondence should be addressed: McArdle Laboratory for Cancer Research, 1400 University Ave., Madison, WI 53706. Tel.: 608-262-1474; Fax: 608-262-2824; E-mail: tcompton@facstaff.wisc.edu.

Published, JBC Papers in Press, August 14, 2001, DOI 10.1074/jbc.M106300200

    ABBREVIATIONS

The abbreviations used are: HCMV, human cytomegalovirus; gB, gH, gL, and gO, glycoprotein B, H, L, and O, respectively; PAGE, polyacrylamide gel electrophoresis; RIPA, radioimmune precipitation; ER, endoplasmic reticulum.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Sinzger, C., and Jahn, G. (1996) Intervirology 39, 302-319[Medline] [Order article via Infotrieve]
2. Turner, A., Bruun, B., Minson, T., and Browne, H. (1998) J. Virol. 72, 873-875[Abstract/Free Full Text]
3. Compton, T., Nowlin, D. M., and Cooper, N. R. (1993) Virology 193, 834-841[CrossRef][Medline] [Order article via Infotrieve]
4. Nowlin, D. M., Cooper, N. R., and Compton, T. (1991) J. Virol. 65, 3114-3121[Abstract/Free Full Text]
5. Spaete, R. R., Perot, K., Scott, P. I., Nelson, J. A., Stinski, M. F., and Pachl, C. (1993) Virology 193, 853-861[CrossRef][Medline] [Order article via Infotrieve]
6. Kaye, J. F., U. A., G., and Minson, A. C. (1992) J. Gen. Virol. 73, 2693-2698[Abstract/Free Full Text]
7. Cranage, M. P., Smith, G. L., Bell, S. E., Hart, H., Brown, C., Bankier, A. T., Tomlinson, P., Barrell, B. G., and Minson, T. C. (1988) J. Virol. 62, 1416-1422[Abstract/Free Full Text]
8. Cranage, M. P., Kouzarides, T., Bankier, A. T., Satchwell, S., Weston, K., Tomlinson, P., Barrell, B., Hart, H., Bell, S. E., Minson, A. C., and Smith, G. L. (1986) EMBO J. 5, 3057-3063[Medline] [Order article via Infotrieve]
9. Milne, R. S., Paterson, D. A., and Booth, J. C. (1998) J. Gen. Virol. 79, 855-865[Abstract]
10. Baghian, B., ZHuang, L., Newman, S., Jayachandra, S., and Kousoulas, K. G. (1993) J. Virol. 67, 2396-2401[Abstract/Free Full Text]
11. Bold, S., Ohlin, M., Garten, W., and Radsak, K. (1996) J. Gen. Virol. 77, 2297-2302[Abstract/Free Full Text]
12. Cai, W., Gu, B., and Person, S. (1988) J. Virol. 62, 2596-2604[Abstract/Free Full Text]
13. Navarro, D., Paz, P., and Pereira, L. (1992) Virology 186, 99-112[CrossRef][Medline] [Order article via Infotrieve]
14. Leatham, M. P., Witte, P. R., and Stinski, M. F. (1991) J. Virol. 65, 6144-6153[Abstract/Free Full Text]
15. Pachl, C., Probert, W. S., Hermsen, K. M., Masiarz, F. R., Rasmussen, L., Merrigan, T. C., and Spaete, R. R. (1989) Virology 169, 418-426[CrossRef][Medline] [Order article via Infotrieve]
16. Li, L., Nelson, J. A., and Britt, W. J. (1997) J. Virol. 71, 3090-3097[Abstract]
17. Huber, M. T., and Compton, T. (1997) J. Virol. 71, 5391-5398[Abstract]
18. Huber, M. T., and Compton, T. (1998) J. Virol. 72, 8191-8197[Abstract/Free Full Text]
19. Huber, M. T., and Compton, T. (1999) J. Virol. 73, 3886-3892[Abstract/Free Full Text]
20. Chee, M. S., Bankier, A. T., Beck, S., Bohni, R., Brown, C. M., Cerny, R., Horsnell, T., Hutchison III, C. A., Kouzarides, T., Martignetti, J. A., Preddie, E., Satchwell, S. C., Tomlinson, P., Weston, K. M., and Barrell, B. G. (1990) Curr. Topics Microbiol. Immunol. 154, 125-169[Medline] [Order article via Infotrieve]
21. Compton, T. (1993) J. Virol. 67, 3644-3648[Abstract/Free Full Text]
22. Sambrook, J., Fritsch, E., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , pp. 1.38-1.41, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
23. Graham, F. L., and van der Eb, A. J. (1973) Virology 52, 456-67[CrossRef][Medline] [Order article via Infotrieve]
24. Fujiki, Y., Hubbard, A. L., Fowler, S., and Lazarow, P. B. (1982) J. Cell Biol. 93, 97-102[Abstract/Free Full Text]
25. Gretch, D. R., Kari, B., Rasmussen, L., Gehrz, R. C., and Stinski, M. F. (1988) J. Virol. 62, 875-881[Abstract/Free Full Text]
26. Britt, W. J. (1984) Virology 135, 369-378[CrossRef][Medline] [Order article via Infotrieve]
27. Nilsson, I., Whitley, P., and von Heijne, G. (1994) J. Cell Biol. 126, 1127-1132[Abstract/Free Full Text]
28. Bos, T. J., Davis, A. R., and Nayak, D. P. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 2327-2331[Abstract/Free Full Text]
29. Wilson-Rawls, J., and Wold, W. S. (1993) Virology 195, 6-15[CrossRef][Medline] [Order article via Infotrieve]
30. Roberts, S. R., Lichtenstein, D., Ball, L. A., and Wertz, G. W. (1994) J. Virol. 68, 4538-4546[Abstract/Free Full Text]
31. Grose, C. (1991) Rev. Infect. Dis. 3, S960-S963
32. Yaswen, L. R., Stephens, E. B., Davenport, L. C., and Hutt-Fletcher, L. M. (1993) Virology 195, 387-396[CrossRef][Medline] [Order article via Infotrieve]
33. Heineman, T., Gong, M., Sample, J., and Kieff, E. (1988) J. Virol. 62, 1101-1107[Abstract/Free Full Text]
34. Rawlinson, W. D., Farrell, H. E., and Barrell, B. G. (1996) J. Virol. 70, 8833-8849[Abstract]
35. Lindquester, G. J., O'Brian, J. J., Anton, E. D., Greenamoyer, C. A., Pellett, P. E., and Dambaugh, T. R. (1997) Arch. Virol. 142, 103-123[CrossRef][Medline] [Order article via Infotrieve]
36. Josephs, S. F., Ablashi, D. V., Salahuddin, S. Z., Jagodzinski, L. L., Wong, S. F., and Gallo, R. C. (1991) J. Virol. 65, 5597-5604[Abstract/Free Full Text]
37. Mukai, T., Hata, A., Isegawa, Y., and Yamanishi, K. (1997) Microbiol. Immunol. 41, 43-50[Medline] [Order article via Infotrieve]
38. Messerle, M., Hahn, G., Brune, W., and Koszinowski, U. H. (2000) Adv. Virus Res. 55, 463-478[CrossRef][Medline] [Order article via Infotrieve]
39. Baldwin, B. R., Kleinberg, M., and Keay, S. (1996) Biochem. Biophys. Res. Commun. 219, 668-673[CrossRef][Medline] [Order article via Infotrieve]
40. Keay, S., and Baldwin, B. (1991) J. Virol. 65, 5124-5128[Abstract/Free Full Text]
41. Mochida, S. (2000) Neurosci. Res. 36, 175-182[CrossRef][Medline] [Order article via Infotrieve]
42. Vogel, K., Cabaniols, J. P., and Roche, P. A. (2000) J. Biol. Chem. 275, 2959-2965[Abstract/Free Full Text]
43. Ilardi, J. M., Mochida, S., and Sheng, Z. H. (1999) Nat. Neurosci. 2, 119-124[CrossRef][Medline] [Order article via Infotrieve]
44. Lao, G., Scheuss, V., Gerwin, C. M., Su, Q., Mochida, S., Rettig, J., and Sheng, Z. H. (2000) Neuron 25, 191-201[CrossRef][Medline] [Order article via Infotrieve]
45. Baldick, C. J., Jr., and Shenk, T. (1996) J. Virol. 70, 6097-6105[Abstract]
46. Spaete, R. R., Gehrz, R. C., and Landini, M. P. (1994) J. Gen. Virol. 75, 3287-3308[Abstract/Free Full Text]
47. Boyle, K. A., and Compton, T. (1998) J. Virol. 72, 1826-1833[Abstract/Free Full Text]
48. Boyle, K. A., Pietropaolo, R. L., and Compton, T. (1999) Mol. Cell. Biol. 19, 3607-3613[Abstract/Free Full Text]
49. Simmen, K. A., Singh, J., Luukkonen, B. G., Lopper, M., Bittner, A., Miller, N. E., Jackson, M. R., Compton, T., and Fruh, K. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 7140-7145[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Virol.Home page
X. J. Jiang, B. Adler, K. L. Sampaio, M. Digel, G. Jahn, N. Ettischer, Y.-D. Stierhof, L. Scrivano, U. Koszinowski, M. Mach, et al.
UL74 of Human Cytomegalovirus Contributes to Virus Release by Promoting Secondary Envelopment of Virions
J. Virol., March 15, 2008; 82(6): 2802 - 2812.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. W. Boehme, M. Guerrero, and T. Compton
Human Cytomegalovirus Envelope Glycoproteins B and H Are Necessary for TLR2 Activation in Permissive Cells
J. Immunol., November 15, 2006; 177(10): 7094 - 7102.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Guma, M. Budt, A. Saez, T. Brckalo, H. Hengel, A. Angulo, and M. Lopez-Botet
Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts
Blood, May 1, 2006; 107(9): 3624 - 3631.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
T. Sadaoka, K. Yamanishi, and Y. Mori
Human herpesvirus 7 U47 gene products are glycoproteins expressed in virions and associate with glycoprotein H.
J. Gen. Virol., March 1, 2006; 87(Pt 3): 501 - 508.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
E. R. Kinzler and T. Compton
Characterization of Human Cytomegalovirus Glycoprotein-Induced Cell-Cell Fusion
J. Virol., June 15, 2005; 79(12): 7827 - 7837.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
S. G. Hansen, L. I. Strelow, D. C. Franchi, D. G. Anders, and S. W. Wong
Complete Sequence and Genomic Analysis of Rhesus Cytomegalovirus
J. Virol., June 15, 2003; 77(12): 6620 - 6636.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
L. Rasmussen, A. Geissler, C. Cowan, A. Chase, and M. Winters
The Genes Encoding the gCIII Complex of Human Cytomegalovirus Exist in Highly Diverse Combinations in Clinical Isolates
J. Virol., October 2, 2002; 76(21): 10841 - 10848.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/42/39226    most recent
M106300200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Theiler, R. N.
Right arrow Articles by Compton, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Theiler, R. N.
Right arrow Articles by Compton, T.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement